Poxel S.A. (EPA:POXEL)

Market Cap	9.50M -45.5%
Revenue (ttm)	7.66M +250.0%
Net Income	-13.66M
EPS	-0.26
Shares Out	53.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,516
Open	0.1860
Previous Close	0.1864
Day's Range	0.1768 - 0.1860
52-Week Range	0.1302 - 0.4800
Beta	1.30
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 18, 2026

About Poxel

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 5
• Stock Exchange: Euronext Paris
• Ticker Symbol: POXEL

Financial Performance

In 2024, Poxel's revenue was 6.64 million, an increase of 234.98% compared to the previous year's 1.98 million. Losses were -18.31 million, -47.83% less than in 2023.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error